© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Victoria Johnson, Assistant Editor for GeneTherapyLive, joined the MJH Life Sciences team in October 2020, originally writing for NeurologyLive. Follow her on Twitter @VictoriaJNeuro or email her at email@example.com.
August 09, 2021
In addition to the uplifted phase 1 study, Novartis also initiated the phase 3 STEER study, which will evaluate OAV-101 in treatment-naive patients with SMA type 2 aged between 2 and 18 years old.
June 17, 2021
While the relationship between sleep and cognition needs to be further studied, sleep-based interventions may be a future approach to help prevent cognitive decline.
June 16, 2021
Santhera and ReveraGen announced findings of the phase 2b VISION DMD study of the investigational therapy.
June 15, 2021
Bayer provided an update on their phase 1 and 1b studies of dopaminergic neurons and GDNF gene therapy, respectively, for the treatment of PD.